Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Subscribe To Our Newsletter & Stay Updated
